Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

(2017) Tomasz M. Beer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

(2016) Jing Liu et al.   CANCER RESEARCH

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia

(2016) Ranjit Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

(2016) Katrin Klocke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

(2016) Claire F. Friedman et al.   JAMA Oncology

A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors

(2015) T. W. Chen et al.   ANNALS OF ONCOLOGY

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

(2013) L. A. Fecher et al.   ONCOLOGIST

Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression

(2013) Tomoyuki Yamaguchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

(2008) Ilyssa O. Gordon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Selective elimination of autoreactive T cells in vivo by the regulatory T cells

(2008) Xing Chang et al.   CLINICAL IMMUNOLOGY